A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

950

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Certolizumab pegol (CDP870)

Trial Locations (76)

Unknown

Huntsville

Paradise Valley

La Jolla

San Diego

Denver

Danbury

Washington D.C.

Aventura

Ocala

Orlando

Sarasota

Tampa

Coeur d'Alene

Springfield

Wichita

Wheaton

St Louis

Lincoln

Charlotte

Cleveland

Dayton

Duncansville

Charleston

Austin

Dallas

San Antonio

Capital Federal

Córdoba

Camperdown

Coffs Harbour

Cotton Tree

Malvern

Shenton Park

Victoria Park

Westmead

Wooloongabba

Antwerp

Brussels

Liège

Merksem

Sijsele

Pleven

Sofia

Stara Zagora

Varna

Courtice

Hamilton

Kitchener

London

Mississauga

Montreal

Newmarket

Point Claire

Sainte-Foy

Toronto

Winnipeg

Valdivia

Santiago

Santiago

Temuco

Rijeka

Brno

Brno Bohunice

Ostrava Trebovice

Pilsen

Prague

Uherské Hradiště

Zlín

Afula

Haifa

Ramat Gan

Tel Aviv

Riga

Moscow

Saint Petersburg

Ivano-Frankivsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY